BTSG Quantifies $200M IRA Hit, Efficiency Claims Need Proof

What happened

A new Zacks report citing management comments quantifies BrightSpring’s 2026 Inflation Reduction Act revenue headwind in Home Pharmacy at $200M, but claims efficiency gains and technology deployment will protect profitability. This matches existing 10-Q evidence that Home & Community Pharmacy revenue already fell 9.2% YoY in Q1’26 due to IRA pricing and rebate mechanics, while company-wide Pharmacy Solutions revenue still rose 25.2% on specialty/infusion mix. The efficiency offset is not yet visible in reported costs: Pharmacy Solutions SG&A jumped 35.7% YoY to $157.0M, outpacing revenue growth and driven by persistent public-company, IT, and growth-support spending. Management has not provided a reconciliation showing how cost actions will offset the $200M revenue loss without further margin pressure, so the claim remains an assertion rather than a demonstrated financial trajectory. The next quarterly filing will be critical to see if SG&A growth decelerates, scripts stabilize, and the raised FY2026 EBITDA guidance of $795M–$825M remains intact.

Implication

For investors, the $200M IRA hit is manageable if—and only if—BrightSpring demonstrates real operating leverage by slowing SG&A growth, holding specialty/infusion gross profit per script near current levels, and avoiding further sponsor secondaries after the early-August lock-up expiry. The current valuation (P/E ~44, EV/EBITDA ~26) embeds flawless execution on mix and costs, leaving no room for error; a miss on EBITDA guidance or another dilutive offering would likely compress the multiple toward the bear-case $58. Watch the 90-day checkpoint: if Q2’26 shows scripts flat-to-up and Pharmacy Solutions SG&A growth decelerating below revenue growth, the efficiency story gains credibility; if SG&A stays elevated and scripts decline again, the WAIT thesis strengthens and the attractive entry remains $55 or below.

Thesis delta

The $200M IRA headwind formalizes a risk already reflected in the WAIT rating but sharpens the near-term earnings bridge: management must now prove efficiency offsets against a known revenue loss. The thesis remains unchanged—wait for evidence that specialty/infusion mix can absorb policy pressure without structurally higher corporate costs, and buy only on a pullback to $55–$58 with no new sponsor overhang.